Clinical Trial Update: Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults [Phase 3]

View source ↗

Summary

Phase 3 results show immunogenicity and safety of GlaxoSmithKline's Boostrix Tdap vaccine in previously boosted young adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Acellular Pertussis | Phase 3 | Status: COMPLETED | Results posted: 2017-12-27